U.S. flag

An official website of the United States government

NM_000500.9(CYP21A2):c.1385T>C (p.Leu462Pro) AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Nov 7, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003479735.1

Allele description [Variation Report for NM_000500.9(CYP21A2):c.1385T>C (p.Leu462Pro)]

NM_000500.9(CYP21A2):c.1385T>C (p.Leu462Pro)

Genes:
LOC106780800:CYP21A2 recombination region [Gene]
CYP21A2:cytochrome P450 family 21 subfamily A member 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
6p21.33
Genomic location:
Preferred name:
NM_000500.9(CYP21A2):c.1385T>C (p.Leu462Pro)
HGVS:
  • NC_000006.12:g.32041031T>C
  • NG_007941.3:g.7727T>C
  • NG_008337.2:g.73344A>G
  • NG_045215.1:g.3260T>C
  • NM_000500.9:c.1385T>CMANE SELECT
  • NM_001128590.4:c.1295T>C
  • NM_001368143.2:c.980T>C
  • NM_001368144.2:c.980T>C
  • NP_000491.4:p.Leu462Pro
  • NP_001122062.3:p.Leu432Pro
  • NP_001355072.1:p.Leu327Pro
  • NP_001355073.1:p.Leu327Pro
  • LRG_829t1:c.1385T>C
  • LRG_829:g.7727T>C
  • LRG_829p1:p.Leu462Pro
  • NC_000006.11:g.32008808T>C
Protein change:
L327P
Molecular consequence:
  • NM_000500.9:c.1385T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001128590.4:c.1295T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001368143.2:c.980T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001368144.2:c.980T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004223436Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Nov 7, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Novel non-classic CYP21A2 variants, including combined alleles, identified in patients with congenital adrenal hyperplasia.

Karlsson L, de Paula Michelatto D, Lusa ALG, D'Almeida Mgnani Silva C, Östberg LJ, Persson B, Guerra-Júnior G, Valente de Lemos-Marini SH, Baldazzi L, Menabó S, Balsamo A, Greggio NA, Palandi de Mello M, Barbaro M, Lajic S.

Clin Biochem. 2019 Nov;73:50-56. doi: 10.1016/j.clinbiochem.2019.07.009. Epub 2019 Jul 22.

PubMed [citation]
PMID:
31344365

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV004223436.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

Variant summary: CYP21A2 c.1385T>C (p.Leu462Pro) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.4e-05 in 142500 control chromosomes (gnomAD). c.1385T>C has been reported in the literature as a compound heterozygous genotype in trans with a pathogenic variant in an individual affected with non-classical Congenital Adrenal Hyperplasia (Karlsson_2019). However, this individual also had a variant in cis which, when expressed together with the variant of interest as a complex variant in vitro, showed a greater reduction of enzyme activity than when either variant was examined in isolation (Karlsson_2019). This report does not provide unequivocal conclusions about association of the variant with Congenital Adrenal Hyperplasia. Experimental evidence evaluating an impact of p.Leu462Pro on protein function found that the variant results in 55% and 40% of WT enzymatic activity towards 17OHP and progesterone, respectively (Karlsson_2019). The following publication has been ascertained in the context of this evaluation (PMID: 31344365). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jan 6, 2024